A
A
Home

Press Releases

2022

June 24, 2022
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
argenx to Present at Upcoming Investor Conferences
May 31, 2022
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
May 19, 2022
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
May 10, 2022
argenx announces results of Annual General Meeting of Shareholders
May 5, 2022
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
May 5, 2022
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
May 4, 2022
argenx to Present at BofA Securities 2022 Healthcare Conference
April 28, 2022
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
April 5, 2022
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
April 1, 2022
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
March 29, 2022
argenx announces full exercise of underwriters’ option to purchase additional ADSs